Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Gaucher disease (type 1, 2, or 3, including subtypes 3a, 3b, and 3c).
- People who have Parkinson's disease that is linked to a change in the GBA gene (a gene connected to Gaucher disease).
Who may not be able to join:
- There are no listed reasons that would prevent someone from joining this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ari Zimran, MD, Shaare Zedek Medical Center
Phone: +972-2-5645681
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Establishing a registry to be used as a reference for patients,parents and physicians, who consider using Ambroxol; Safety Outcome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.